This is a secondary analysis of 621 women in ROLO study, a randomized control trial of low glycemic index (GI) diet in pregnancy to prevent the recurrence of macrosomia, which aims to assess the effect of the diet on maternal and fetal insulin resistance, leptin, and markers of inflammation. In early pregnancy and at 28 weeks, serum was analyzed for insulin, leptin, tumor necrosis factor a (TNF-a), and interleukin 6 (IL-6). At delivery, cord blood concentrations of leptin, TNF-a, IL-6, and C-peptide were recorded. We found no difference between those who did or did not receive low GI advice with respect to the concentrations of any marker in early pregnancy, at 28 weeks or in cord blood. Women in the intervention arm of the study did have a lower overall rise in insulin concentrations from early pregnancy to 28 weeks gestation, P ¼ .04. Of the women in the intervention arm, 20% were in the highest quartile for insulin change (28-week insulin À insulin at booking) compared to 29% of controls (P ¼ .02). In conclusion, a low GI diet in pregnancy has little effect on leptin and markers of inflammation although an attenuated response to the typical increase in insulin resistance seen in pregnancy with advancing gestation was seen in those who received the low GI advice.
Introduction
Intrauterine growth and development are subject to a host of maternal, environmental, and genetic factors. Rates of intrauterine growth, particularly if restrictive or excessive, can have profound and lasting implications for later adult health. 1, 2 In particular, the large for gestational age fetus is predisposed to a variety of adverse obstetric and neonatal outcomes, and delivery of a large infant significantly increases the risk of birth complications for the mother. 3, 4 In the long term, infants who are at the highest end of the distribution for weight or body mass index (BMI) are more likely to be obese in childhood, adolescence, and early adulthood than other infants 5 and are at risk of cardiovascular and metabolic complications later in life. 6, 7 The primary maternal environmental factor that regulates feto-placental growth is substrate delivery to the placental site, and glucose is the main energy substrate for intrauterine growth. 8 The predominant dietary source of glucose comes from carbohydrates. Different carbohydrate foods produce different glycemic responses, and carbohydrates are classified according to their induced glycemic response as either high or low glycemic index (GI). 9 We recently reported the results of the ROLO study, a randomized control trial of low GI diet in pregnancy to prevent the recurrence of macrosomia, in a group of women who had previously given birth to infants weighing greater than 4000 g. 10 The ROLO study established that a low GI diet in pregnancy had no effect on infants' birth weight in a group at risk of fetal macrosomia. It did, however, have a significant positive effect, with less gestational weight gain and less maternal glucose intolerance.
In order to further probe the effects of this intervention on maternal and fetal metabolism, we performed an analysis of maternal and fetal insulin resistance and leptin. Furthermore, due to increasing data linking pro-and anti-inflammatory mediators in the pathogenesis of obesity-related consequences, and, in particular, the development of insulin resistance and overt diabetes mellitus, 11, 12 we also compared concentrations of tumor necrosis factor a (TNF-a) and interleukin 6 (IL-6) between the 2 groups. Our hypothesis was that a low GI diet in pregnancy would result in less maternal insulin resistance, lower leptin concentrations, and lower levels of inflammatory markers in both mother and fetus.
Methods
This is a nested cohort study of 621 mother and infant pairs recruited to the ROLO study with institutional ethical approval and written informed maternal consent. 13 Women were excluded if they had any underlying medical conditions, if they were less than 18 years of age, if they had previous gestational or preexisting type 1 or type 2 diabetes, or if they were unable to give full informed consent. For the purposes of this secondary analysis, those with incomplete blood results were also excluded (n ¼ 138). At recruitment and at 28 weeks, all women had measurement of weight, height, and upper arm circumference, and fasting serum glucose, fasting serum was analyzed for glucose, insulin, leptin, TNF-a, and IL-6.
At delivery, infant birth weight, infant length, and head circumference were recorded, and a cord blood sample was taken for the measurement of concentrations of fetal glucose, leptin, C-peptide, TNF-a, and IL-6.
Multianalyte profiling was performed on the Luminex Magpix system (Luminex Corporation, Austin, Texas.). The Human Endocrine Panel determined plasma concentrations of leptin, insulin, and C-peptide. Maternal insulin resistance was calculated using the homeostatic model assessment (HOMA) index: HOMA score ¼ (fasting insulin mU/mL Â fasting glucose mmol/L)/22.5. Fetal insulin resistance was assessed with cord blood C-peptide estimation.
14 Data were assessed for normality using Shapiro-Wilk and P-P plot. None of the analytes were normally distributed. A comparison of medians between the groups was accomplished using the Mann-Whitney U test. Further analysis was performed by calculating the interquartile range for each analyte overall and comparing the proportion of patients in the lowest and the highest quartiles between the intervention and the control arms of the study using chi-square test.
To assess adherence to the low GI diet, we gave patients in the intervention group a questionnaire at their 34-week antenatal visit. This was based on a 5-point Likert-type scale (1 ¼ I followed the recommended diet all of the time; 5 ¼ I followed the recommended diet none of the time).
As pregnancy is a state of physiologically increased insulin resistance, particularly in the third trimester, a final analysis was performed comparing the change in insulin from early pregnancy to 28 weeks between the 2 groups. Statistical significance was set at P < .05. Statistical analysis was performed using SPSS Windows's version 18.0 (SPSS, Chicago, Illinois).
Results
Patients were recruited at first antenatal consultation at 13.8 + 2.4 weeks. There was no difference between the 2 groups in either fasting insulin or the HOMA index at 28 weeks gestation following the intervention (Table 1) . Similarly, no difference was noted in cord blood C-peptide between those who did and those who did not receive low GI dietary advice in early pregnancy.
Women in the intervention arm of the study did have a lower overall rise in insulin concentrations from early pregnancy to 28 weeks gestation (Table 1) . When the proportion of women within the highest versus the lowest quartile for the cohort was compared, 20% of women in the intervention arm were in the highest quartile for insulin change (28-week insulin À insulin at booking) compared to 29% of the controls (P ¼ .02; Table 2 ). There was no difference between the 2 groups in serum leptin concentrations in early pregnancy prior to intervention, at 28 weeks gestation, or in cord blood at delivery when compared using Mann-Whitney U test. Similarly, no difference existed between the 2 groups in terms of the proportion of women in the highest compared to the lowest quartile of leptin concentrations for the cohort using chi-square test (Tables 1 and 2 ).
There was no difference between those who did and those who did not receive low GI dietary advice with respect to the concentrations of either TNF-a or IL-6 in early pregnancy prior to intervention, at 28 weeks gestation, or in cord blood at delivery when compared using Mann-Whitney U test. Similarly, no difference existed between the 2 groups in terms of the proportion of women in the highest compared to the lowest quartile of TNF-a or IL-6 concentrations for the cohort using chi-square test (Tables 1 and 2 ). Almost 80% (n ¼ 294) of the intervention arm reported following the low GI dietary advice either all or most of the time on the adherence questionnaire.
Discussion
In summary, we have found that a low GI diet in pregnancy has little effect on markers of maternal insulin resistance or inflammation in a cohort of euglycemic women at risk of macrosomia. We did note an attenuated response to the typical increase in insulin resistance, seen in pregnancies in Westernized countries, with advancing gestation in those who received the low glycemic dietary advice although the overall effect was limited.
The ROLO study did identify a lower rate of glucose intolerance in the intervention arm overall, with significantly less women on the low GI diet having either a fasting glucose concentration of greater than 5.1 mmol/L or a glucose challenge test of greater than 7.8 mmol/L following a 50 g glucose load (21% vs 28%, P < .05). 13 The rate of gestational diabetes in the study cohort overall, however, was low, with just 7 in the intervention and 9 in the control arm according to Carpenter and Coustan criteria (or 12 vs 18 according to the American Diabetes Association criteria). 15, 16 This low rate may account for the lack of difference seen in the current analysis.
Data in the literature pertaining to leptin and markers of inflammation and pregnancy relate predominantly to obese and diabetic populations. Leptin is an adipokine that is secreted from adipose tissue and concentrations rise significantly with increasing percentage of body fat. 17 Inflammatory markers are equally produced by adipose tissue and are known to regulate fat deposition and appetite. 18 Although the ROLO trial did result in less gestational weight gain in women who received the low GI dietary advice, it was not a trial of obese and overweight women. The mean BMI of our study participants was 26.8 + 5.1 kg/m 2 in early pregnancy. The strict inclusion criteria of the ROLO study, which excluded those with previous gestational or preexisting diabetes mellitus, those with any underlying medical conditions, and those with a previous poor obstetric outcome, are likely to have excluded women with underlying metabolic derangements which may predispose them in insulin resistance. Equally, the trial was powered for the primary outcome, birth weight, and not for the secondary analysis of maternal and fetal metabolic factors, and the use of multiple comparisons may have resulted in a type 1 statistical error. Our study group likely represents a heterogeneous population, comprising healthy women giving birth to genetically healthy large infants; women with subthreshold gestational diabetes who are giving birth to infants that are large due to a relative maternal hyperglycemia and perhaps a third cohort of women who are giving birth to infant that are large due to a pathological process other than maternal hyperglycemia /fetal hyperinsulinemia.
Moreover, it has been suggested that the proportion of infants weighing greater than 4000 g who are larger than expected due to excess glucose transfer across the placenta as detected by fetal cord hyperinsulinemia may be as low as 15% to 20%. 19 A major difficultly therefore lies in the identification of pregnancies that are going to result in pathological growth secondary to maternal metabolic derangements and that may therefore benefit from any dietary or lifestyle intervention prenatally.
The pathogenesis underlying the fetal programming of later metabolic health and obesity is complex and multifactorial but is likely to relate to the metabolic milieu of the intrauterine environment.
Further studies are now needed to clarify whether pregnancy interventions, such as dietary and lifestyle modifications, can result in improvements in maternal and fetal insulin resistance and metabolism. It would appear from these results that such studies would be best suited to women specifically at risk of metabolic dysfunction, such as the overweight, obese, and diabetic populations.
